#ESMO26 🧬 COMPANION-002 | III期
👥 既往接受过治疗的 BTC
💊 紫杉醇 + tovecimig vs 紫杉醇
🎯 ORR：18% vs 5.3%
📈 mPFS：4.7 vs 2.6 个月
⏳ mOS：8.9 vs 9.4 个月
❌ 尽管 ORR 和 PFS 有所改善，但未带来 OS 获益。
💡 活性令人鼓舞，但尚非新的 SoC
@OncoAlert
15 浏览 · 0 赞 · 0 转发 · 0 回复
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com